Two sets of gene expression profiles predict response to a common lung cancer drug for patients that have no guiding indicators for their treatment now, scientists from The University of Texas MD Anderson Cancer Center report at the AACR 102nd Annual Meeting.
"The only way we have to predict erlotinib's treatment benefit for patients now is by checking for certain mutations and amplifications of the epidermal growth factor receptor (EGFR), and that only covers about 12 percent of patients," said John Heymach, M.D., Ph.D., associate professor in MD Anderson's Department of Thoracic/Head and Neck Oncology.
Erlotinib, known commercially as Tarceeva, inhibits EGFR.
"We know there are other groups of patients who benefit from erlotinib, but right now we can't identify them in advance," Heymach said. "These two biomarker sets have potentially broad impact by covering the 88 percent of patients who lack EGFR mutations."
Using a five-gene signature and a group of genes involved in a certain type of cell transition, Heymach and colleagues developed biomarkers that indicate treatment benefit for patients with normal EGFR. They also identified one gene in each set a potential targets for new drugs, Heymach said.
The biomarkers were developed by analyzing data from the Biomarker-integrated Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) clinical trial conducted at MD Anderson. BATTLE analyzed the use of pre-specified biomarkers to guide treatment among four options.
"Last year, we presented results on pre-specified markers to determine how effective they would be at predicting response to EGFR inhibition," Heymach said. "This year, we looked for gene responses that had not been chosen in advance for BATTLE."
The researchers analyzed core needle biopsies of 101 BATTLE clinical trial patients and also looked at 54 non-small cell lung cancer lines to find genes involved in epithelial-to-mesenchymal transition (EMT). Cancer cells that change from stationary cells (epithelial) that line organs into mobile mesenchymal cells become more invasive, resistant to treatment and are associated with metastasis.
The endpoint for BATTLE was disease control after 8 weeks. The team found:
Both sets of signatures will be tested prospectively in the upcoming BATTLE II clinical trial, along with markers from the PI3K-AKT pathway, EGFR signatures and KRAS mutations. The four treatment arms of the trial are erlotinib, sorafenib (Nexavar), erlotinib plus an AKT inhibitor and the AKT inhibitor with a MEK inhibitor.
Co-investigators with Heymach are: Pierre Saintigny, M.D., You Fan, Xi Ming Tang, Edward Kim, M.D., Roy Herbst, M.D., Ph.D., Anne Tsao, M.D., George Blumenschein, M.D., Scott Lippman, M.D., and Waun Ki Hong, all of MD Anderson's Department of Thoracic/Head and Neck Medical Oncology; Lixia Diao, Jing Wang, Ph.D., Kevin Coombes, Ph.D., and John Weinstein, M.D., Ph.D., of MD Anderson's Department of Bioinformatics and Computational Biology; Suyu Liu and J. Jack Lee, Ph.D., MD Anderson's Department of Biostatistics; Steven H. Lin, M.D., Ph.D., MD Anderson's Department of Radiation Oncology; Ignacio I. Wistuba, M.D., of MD Anderson's Department of Pathology; Li Mao, M.D., of the University of Maryland, Baltimore, Dental School Department of Oncology and Diagnostic Science; Luc Girard, Ph.D., The University of Texas Southwestern Medical School Department of Pharmacology; Yang Xie, Ph.D., UT-Southwestern Simmons Comprehensive Cancer Center, and John Minna, M.D., UT- Southwestern Medical School Hamon Center for Therapeutic Oncology Research,
Funding was provided by the U.S. Department of Defense, the MD Anderson and UT Southwestern Lung Cancer Specialized Program in Research Excellence, and MD Anderson's Cancer Center Support Grant from the National Cancer Institute.
Materials provided by University of Texas M. D. Anderson Cancer Center. Note: Content may be edited for style and length.
Cite This Page: